TMCx孵化器展示21家医疗创业公司-DOT耳机(5/21)

TMCx孵化器展示21家医疗创业公司-DOT耳机(5/21)


位置:加拿大渥太华

DOT提供更加精确的可穿戴式消费设备,设备能诊治像ADHD(注意缺陷多动障碍)这样的精神紊乱症。核心产品是一款神经反馈耳机,可与互动应用程序配合,通过将神经反馈治疗游戏化来提供个性化诊断和治疗。“这将成为我们进入美国的切入点。我们希望通过与儿童健康领域中的协会和领军机构合作,在美国市场上获得发展。”首席执行官 Yishel Khan表示。

DOT is a Canadian Healthcare Software/Hardware Solution Company that serves the increasing need for more precise and effective medical devices that diagnose and treat mental disorders like ADHD. DOT is developing and offering a solution of interactive software paired with neurofeedback hardware, to provide quantitative diagnosis and treatment of children with ADHD. These solutions will be offered primarily to parents of children with ADHD, as well as directly to mental health practitioners for use in their clinics. DOT is currently allied, advised and supported by a strong array of healthcare experts, institutions and medical practitioners.

VISION & MISSION Our mission is to better the lives of ADHD sufferers, using a data-driven approach to mental health to guide parents and healthcare practitioners to optimal decisions about children’s treatment. Our vision is to make mental health therapies across the world more a) personalized, b) measurable, c) effective and d) accessible. DOT will become the world’s leading platform for mental disorder diagnostics, complimenting existing mental health care options with diagnostics and treatment that are driven both by quantitative analytics and a deep respect for the needs of each and every individual, no matter where they live.

COMPANY HISTORY DOT started at the WearHacks Hackathon, and won several awards thereafter at conferences such as Hacking Health and Design Challenge Montreal. DOT received a scholarship to the Founder Institute pre-accelerator program, and successfully graduated in summer 2015 having satisfied its requirements for technical feasibility, market potential and validation and financial viability. The product concept has been validated in market surveys, website visitor conversions, medical expert interviews, as well as a limited proof of concept developed with research from the McGill University neuroscience researchers.